Overview
Japanese Encephalitis Virus (JEV) RNA PCR – Qualitative is an advanced molecular diagnostic test used for the early detection of Japanese Encephalitis virus infection. The test identifies the presence of viral genetic material (RNA) in clinical samples and is considered an optimal method for confirming acute infection during the early phase of disease.
Japanese Encephalitis is a severe mosquito-borne viral illness and remains one of the most important causes of viral encephalitis in Asia. Early and accurate diagnosis is crucial for timely clinical management, especially in patients presenting with acute encephalitis syndrome. This test is performed on cerebrospinal fluid, serum, or whole blood and is most effective when samples are collected during the initial phase of symptoms.
Pathophysiology of Japanese Encephalitis Virus
Japanese Encephalitis Virus is a single-stranded RNA virus belonging to the flavivirus group, which also includes dengue, yellow fever, and West Nile viruses. The virus is transmitted to humans through the bite of infected Culex mosquitoes.
The natural transmission cycle involves mosquitoes and amplifying hosts such as pigs and wading birds. Humans are incidental dead-end hosts and do not contribute to further transmission. After a mosquito bite, the virus initially multiplies at the site of inoculation and in nearby lymph nodes. A brief viremia follows, which is usually cleared by the immune system in most individuals, resulting in asymptomatic or mild infection.
In severe cases, the virus crosses the blood–brain barrier and infects the central nervous system. This leads to inflammation and edema in the cerebral hemispheres, brainstem, cerebellum, and occasionally the spinal cord. Petechial hemorrhages may be present in severe infections, contributing to neurological damage.
Symptoms
The incubation period of Japanese Encephalitis typically ranges from 5 to 15 days. Initial symptoms include fever, headache, and vomiting. As the disease progresses, neurological symptoms such as disorientation, weakness, seizures, coma, and paralysis may develop.
Seizures are particularly common in children. Although more than 99% of infected individuals remain asymptomatic or experience only mild illness, less than 1% develop severe neurological disease. Among these patients, mortality ranges from 20% to 25%. Survivors often experience long-term neurological, cognitive, or psychiatric complications, with 30% to 50% showing lasting deficits.
Indications for JEV RNA PCR Testing
JEV RNA PCR testing is indicated in patients with evidence of acute encephalitis syndrome who have recently traveled to or resided in endemic regions of Asia or the Western Pacific.
The test is especially useful when the clinical presentation is unclear or atypical, but suspicion of JEV remains high. Even in the presence of other possible arthropod-borne viral infections, JEV PCR testing is recommended when epidemiological risk exists. The assay is also valuable during outbreaks to screen populations and trace sources of infection.
Principle of the Test
The test is based on selective and exponential amplification of a specific RNA segment of the Japanese Encephalitis virus. Viral RNA is first converted into complementary DNA, which is then amplified using the polymerase chain reaction.
Three fundamental steps are involved: denaturation, annealing, and extension. These steps are repeated through multiple cycles in a thermocycler, generating millions of copies of the target sequence. The test detects only the presence or absence of viral RNA and does not provide quantitative viral load information.
Sample Collection and Handling
Samples suitable for testing include cerebrospinal fluid, whole blood, or serum. Approximately 2.0 mL of sample is collected in EDTA (lavender-capped) tubes or plain red-capped tubes. Serum should be separated as early as possible.
The specimen is transferred to viral transport medium in a 1:1 ratio. Proper collection technique is critical, as improper sampling may lead to false-negative results. Clinical history, including onset of symptoms, vaccination status, travel history, and exposure details, should be provided with the sample.
Storage and Transport
After transfer to viral transport medium, samples may be refrigerated at 2–8°C for up to 72 hours. Specimens should reach the laboratory as soon as possible.
If testing is delayed beyond 72 hours, samples should be frozen at –20°C or lower. Samples stored at –70°C must be transported on dry ice. Repeated freeze–thaw cycles should be avoided to preserve RNA integrity.
Interpretation of Results
A positive result indicates detection of Japanese Encephalitis viral RNA and confirms acute infection. A negative result indicates no detectable viral RNA at the time of testing.
Because viral RNA levels decline rapidly, a negative result does not exclude infection if sampling is delayed. In such cases, follow-up testing with serological assays may be required. Intermediate or undetermined results should be correlated with clinical findings and other laboratory data.
Cycle threshold (Ct) values are used internally by the testing laboratory. Lower Ct values indicate higher viral RNA presence, while undetected Ct values indicate the absence of detectable viral RNA.
Advantages
JEV RNA PCR offers rapid and highly sensitive detection of infection, particularly in the early stage. The test has high specificity, reducing the risk of false-positive results.
Automation minimizes technical errors, and early detection supports prompt clinical decision-making. The assay is especially valuable during outbreaks for large-scale screening.
Limitations
The test is costly and requires specialized equipment and trained personnel. Improper sample collection or delayed testing may result in false-negative results.
Availability may be limited in certain regions, and PCR sensitivity decreases as viremia declines. Therefore, results must always be interpreted in conjunction with clinical presentation and epidemiological data.
